Evidence map›Paper›PMID 22718316›Full record

ArticleJournal of cellular physiology2013

Impaired pulmonary defense against Pseudomonas aeruginosa in VEGF gene inactivated mouse lung.

Ellen C Breen, Jaret L Malloy, Kechun Tang, Feng Xia, Zhenxing Fu, Robert E W Hancock, Joerg Overhage, Peter D Wagner, Roger G Spragg

Abstract read
In one paragraph

Article in Journal of cellular physiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 3 countries.

Ellen C BreenDivision of Physiology, Department of Medicine, University of California, San Diego, La Jolla, California 92093-0623, USA. ebreen@ucsd.edu
Jaret L Malloy
Kechun Tang
Feng Xia
Zhenxing Fu
Robert E W Hancock
Joerg Overhage
Peter D Wagner
Roger G Spragg
University of California, San Diego · USInstitute of Infection and Immunity · CA

Funding

VENTILATION BLOOD FLOW IN HEALTH AND DISEASEP01HL017731 · NHLBI · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI WAGNER, PETER D · 1985 to 2004
$10.6M
CIHRNHLBI NIH HHS P01 HL017731NHLBI NIH HHS P01 HL 17731-28
6 · The paper itself

Abstract

Repeated bacterial and viral infections are known to contribute to worsening lung function in several respiratory diseases, including asthma, cystic fibrosis, and chronic obstructive pulmonary disease (COPD). Previous studies have reported alveolar wall cell apoptosis and parenchymal damage in adult pulmonary VEGF gene ablated mice. We hypothesized that VEGF expressed by type II cells is also necessary to provide an effective host defense against bacteria in part by maintaining surfactant homeostasis. Therefore, Pseudomonas aeruginosa (PAO1) levels were evaluated in mice following lung-targeted VEGF gene inactivation, and alterations in VEGF-dependent type II cell function were evaluated by measuring surfactant homeostasis in mouse lungs and isolated type II cells. In VEGF-deficient lungs increased PAO1 levels and pro-inflammatory cytokines, TNFα and IL-6, were detected 24 h after bacterial instillation compared to control lungs. In vivo lung-targeted VEGF gene deletion (57% decrease in total pulmonary VEGF) did not alter alveolar surfactant or tissue disaturated phosphatidylcholine (DSPC) levels. However, sphingomyelin content, choline phosphate cytidylyltransferase (CCT) mRNA, and SP-D expression were decreased. In isolated type II cells an 80% reduction of VEGF protein resulted in decreases in total phospholipids (PL), DSPC, DSPC synthesis, surfactant associated proteins (SP)-B and -D, and the lipid transporters, ABCA1 and Rab3D. TPA-induced DSPC secretion and apoptosis were elevated in VEGF-deficient type II cells. These results suggest a potential protective role for type II cell-expressed VEGF against bacterial initiated infection.

Indexed as

Pseudomonas aeruginosaAnimalsATP Binding Cassette Transporter 1ATP-Binding Cassette TransportersCholine-Phosphate CytidylyltransferaseCytokinesFemaleGene SilencingLungLung DiseasesMaleMicePhosphatidylcholinesPhospholipidsPseudomonas InfectionsPulmonary SurfactantsATP Binding Cassette Transporter 1ATP-Binding Cassette TransportersCholine-Phosphate CytidylyltransferaseCytokinesPhosphatidylcholinesPhospholipidsPulmonary SurfactantsRab3d protein, mouserab3 GTP-Binding ProteinsSphingomyelinsVascular Endothelial Growth Factor Avascular endothelial growth factor A, mouse

Identifiers

PMID22718316
PMCPMC3484242
OpenAlexW2006144719

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.